25,131 Shares in Jade Biosciences, Inc. $JBIO Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd purchased a new stake in shares of Jade Biosciences, Inc. (NASDAQ:JBIO) in the first quarter, Holdings Channel.com reports. The fund purchased 25,131 shares of the company’s stock, valued at approximately $353,000.

Other institutional investors have also recently bought and sold shares of the company. Legal & General Group Plc acquired a new position in Jade Biosciences in the second quarter worth $29,000. Russell Investments Group Ltd. acquired a new stake in shares of Jade Biosciences in the second quarter valued at $31,000. BNP Paribas Financial Markets acquired a new stake in shares of Jade Biosciences in the second quarter valued at $32,000. California State Teachers Retirement System raised its holdings in shares of Jade Biosciences by 40.3% in the fourth quarter. California State Teachers Retirement System now owns 2,850 shares of the company’s stock valued at $44,000 after buying an additional 819 shares during the last quarter. Finally, Group One Trading LLC raised its holdings in shares of Jade Biosciences by 122.9% in the fourth quarter. Group One Trading LLC now owns 4,195 shares of the company’s stock valued at $65,000 after buying an additional 22,527 shares during the last quarter.

Analyst Ratings Changes

JBIO has been the topic of a number of research analyst reports. Jefferies Financial Group reissued a “buy” rating on shares of Jade Biosciences in a report on Monday, June 1st. BTIG Research raised their price objective on shares of Jade Biosciences from $39.00 to $74.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Zacks Research raised shares of Jade Biosciences from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 8th. Guggenheim reiterated a “buy” rating and set a $47.00 target price on shares of Jade Biosciences in a research report on Tuesday, June 2nd. Finally, Weiss Ratings cut shares of Jade Biosciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, June 16th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $51.57.

Jade Biosciences Stock Up 0.2%

JBIO stock opened at $21.34 on Wednesday. The business’s fifty day moving average is $20.68 and its 200-day moving average is $17.78. The company has a market cap of $1.05 billion, a P/E ratio of -10.56 and a beta of 1.43. Jade Biosciences, Inc. has a twelve month low of $6.67 and a twelve month high of $28.00.

Jade Biosciences (NASDAQ:JBIO) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.05). Research analysts anticipate that Jade Biosciences, Inc. will post -2.54 earnings per share for the current fiscal year.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.